Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-24 @ 7:11 PM
NCT ID:
NCT03535103
Eligibility Criteria:
Inclusion Criteria:
1. Able and willing to provide written informed consent.
2. Agreed to take effective contraceptive measures during and 6 months after the end of the study period.
3. Age between 18 to 40 years (inclusive).
4. Body weight ≥45 kg, body mass index (BMI) of ≥18 and ≤28 kg/m2,
5. Regular menstruation cycle (25 to 34 days, inclusive).
6. Normal findings in sex hormone examinations, including FSH, LH, prolactin (PRL), estradiol (E2), progesterone (P), testosterone (T) unless the investigator considers an abnormality to be clinically irrelevant for this study.
Exclusion Criteria:
1. Smoke ≥5 cigarettes or the equivalent per day within 3 months prior to the study
2. History of hypersensitivity to FSH, or hypersensitivity to luteinizing hormone releasing hormone agonist or something like that.
3. Historic abuse of alcoholic beverages and drugs (Drink 14 units of alcohol/week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine.
4. Taken any liver enzyme activity relative drug within 28 days prior to the screening.
5. Take any prescription drug, OTC drug, vitamin product or herbal medicine within 14 days prior to the screening.
6. Taken special diets (including pitaya, mango, grapefruit, etc.) or have strenuous exercise, or something affect the absorption, distribution, metabolism, excretion, etc. of the drug within 2 weeks prior to the study.
7. Major changes in diet or exercise habits recently
8. Participation in a clinical study within 3 months prior to the study.
9. Acute disease or combination therapy from the screening to the beginning time of the study.
10. Take any alcoholic product within 48 hours prior to the study.
11. Take chocolate, any caffeine-containing or xanthine-rich food or drinks within 48 hours prior to using the drug;
12. Blood donation or massive blood losing (\>450mL) within 3 months prior to the screening;
13. Viral hepatitis (including hepatitis B and hepatitis C), HIV, and Treponema pallidum positive.
14. History of significant diseases such as circulatory, endocrine, neurological, reproductive, digestive, and respiratory systems, hematology, immunology, psychiatry, and metabolic abnormalities, or past or current medical history that could interfere with the test results, eg subjects with or have suffered from hypothyroidism, adrenocortical insufficiency and hyperprolactinemia, polycystic ovary syndrome, and ovarian dysfunction, premature ovarian failure (POI) or primary ovarian failure, unexplained uterine bleeding, hypothalamic or pituitary tumors, ovarian, uterine or breast cancer, history of thrombosis, history of malignancy;
15. Baseline of serum FSH ≥15 IU/L.
16. History of ovarian hyperstimulation syndrome (OHSS).
17. Other abnormalities judged by researchers of the study
18. Abnormal physical examination and clinical significance judged by researchers of the study
19. Abnormal vital signs and clinical significance judged by researchers of the study.
20. Abnormal laboratory tests with clinically relevance.
21. Abnormal electrocardiogram \[ECG\] findings.
22. III/IV class endometriosis, submucous myoma of uterus, endocrine abnormalities within 6 months prior to the study.
23. Abnormal imaging examination and clinical significance judged by researchers of the study, such as with a uterine fibroid diameter ≥ 40 mm.
24. Pregnancy or lactation period.
25. Alcohol screening positive.
26. Urine drug screening positive
Healthy Volunteers:
True
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
40 Years
Study:
NCT03535103
Study Brief:
Protocol Section:
NCT03535103